Who was studied?
Patients with borderline resectable or unresectable locally advanced pancreatic ductal adenocarcinoma.
What does the publication report?
Phase I evaluates radiation dose and safety; phase II plans to evaluate one-year OS and resection-related outcomes.
Safety findings
Safety and tolerability are phase I objectives; this protocol has no completed safety results.
How should we interpret it?
This is a study protocol, not a report of treatment results. Planned enrollment and endpoints are not observed outcomes.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
A Phase I/II Study Protocol of a Novel Neoadjuvant 'PRaG' Regimen (Radiotherapy, GM-CSF, and Cadonilimab) with AG Chemotherapy to Improve Resectability in Locally Advanced Pancreatic Ductal Adenocarcinoma: The NeoPRAG Study · DOI: 10.1177/15330338251399255 · PMID: 41252443
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.